Skip to main content
. 2008 Apr 9;15(6):986–994. doi: 10.1128/CVI.00492-07

FIG. 4.

FIG. 4.

Summary of vaccine (n = 32) and placebo (n = 8) recipients recognizing vaccine peptides using primary and expanded ELISPOT assays. The percentage of recipients responding to one or more (solid bars) or two or more (hatched bars) epitope peptides using the following criteria are shown: primary ELISPOT assay (prevaccine versus week 18, unexpanded PBMCs), primary cumulative (prevaccine versus any postvaccine time point, unexpanded PBMCs), or IVS ELISPOT assay (prevaccine versus week 24, expanded PBMCs).